Industries > Pharma > Asthma & COPD Therapies Market Report 2023-2033

Asthma & COPD Therapies Market Report 2023-2033

Forecasts by Product (Anti-inflammatory Drugs, Bronchodilators Monotherapy, Combination Drugs), by Route of Administration (Oral, Inhaled, Others), by Point of Sale (Retail Pharmacies, Hospital Pharmacies, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

PUBLISHED: 03 January 2023
PAGES: 248
PRODUCT CODE: PHA1223
SUBMARKET: Therapeutic Drugs

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA1223 Categories: , Tags: , , ,

The Asthma & COPD Therapies Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Expansion into Emerging Markets to Offer Lucrative Growth Opportunities
For the overall asthma and COPD market, expansion into the emerging markets will be of high importance in the years to come, in particular as the US and European markets become saturated and experience slow growth or decline due to patent expiry, generic competition and low healthcare budgets. The economic troubles currently being experienced in a number of emerging markets are likely to lift over the next ten years, returning those nations to continued expansion of their healthcare systems and satisfaction of unmet treatment needs. Inhaled drugs will continue to be less affected by patent expiries, as long as the inhaler patents are intact. Advances in inhaler design will continue to be of vital importance to the market.

Nevertheless, the asthma and COPD market have a potential for a number of blockbuster drugs with increasingly segmented sub-groups of patients. The market also benefits from increasing prevalence of respiratory diseases, coupled with the high economic cost of those diseases, revenues are expected to increase in the years to come. New combination drugs will drive growth. The industry will also have more biologics and synthetic anti-inflammatory agents for both asthma and COPD, as companies look to identify and offer treatments for multiple patient sub-groups. Future success will on long-term planning, to maximise the revenues for existing drugs (life cycle management), to successfully expand into emerging markets and to identify and address unmet needs in the patient population depend on novel and effective therapies.

What Questions Should You Ask before Buying a Market Research Report?
• How is the asthma & COPD therapies market evolving?
• What is driving and restraining the asthma & COPD therapies market?
• How will each asthma & COPD therapies submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each asthma & COPD therapies submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading asthma & COPD therapies markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the asthma & COPD therapies projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of
asthma & COPD therapies projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the asthma & COPD therapies market?
• Where is the asthma & COPD therapies market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the asthma & COPD therapies market today, and over the next 10 years:
• Our 248-page report provides 107 tables and 130 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the asthma & COPD therapies market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Product
• Anti-inflammatory Drugs
• Bronchodilators Monotherapy
• Combination Drugs

Route of Administration
• Oral
• Inhaled
• Others

Point of Sale
• Retail Pharmacies
• Hospital Pharmacies
• Others

CTA

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe

Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

Asthma & COPD Therapies Market Report 2023-2033
Need industry data? Please contact us today.

The report also includes profiles and for some of the leading companies in the Asthma & COPD Therapies Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• AstraZeneca
• Boehringer Ingelheim
• Chiesi Farmaceutici S.p.A.
• Cipla Inc.
• F. Hoffmann-La Roche Ltd.
• Grifols S.A.
• GSK plc
• Mundipharma
• Novartis AG
• Pulmatrix
• Respiratorius AB
• Sanofi SA
• Sunovion Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd.
• TFF Pharmaceuticals, Inc.
• Transpire Bio
• Verona Pharma plc
• Viatris Inc.

Overall world revenue for Asthma & COPD Therapies Market, 2023 to 2033 in terms of value the market will surpass US$47 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Asthma & COPD Therapies Market, 2023 to 2033 report help you?
In summary, our 240+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Asthma & COPD Therapies Market, 2023 to 2033 Market, with forecasts for Product, Route of Administration, and Point of Sale, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for five regional and 20 key national markets – See forecasts for the Asthma & COPD Therapies Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 18 of the major companies involved in the Asthma & COPD Therapies Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Asthma & COPD Therapies Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Asthma & COPD Therapies Market Report 2023-2033: Forecasts by Product (Anti-inflammatory Drugs, Bronchodilators Monotherapy, Combination Drugs), by Route of Administration (Oral, Inhaled, Others), by Point of Sale (Retail Pharmacies, Hospital Pharmacies, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Asthma & COPD Therapies Market Report 2023-2033

    Download sample pages

    Complete the form below to download your free sample pages for Asthma & COPD Therapies Market Report 2023-2033

      Latest Pharma news

      Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033

      The global Allergy Immunotherapy market is projected to grow at a CAGR of 7.6% by 2033

      31 May 2023

      READ

      Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033

      The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.

      26 May 2023

      READ

      Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033

      The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033

      24 May 2023

      READ

      Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033

      The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033

      23 May 2023

      READ